Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

591 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation.
László T, Kotmayer L, Fésüs V, Hegyi L, Gróf S, Nagy Á, Kajtár B, Balogh A, Weisinger J, Masszi T, Nagy Z, Farkas P, Demeter J, Istenes I, Szász R, Gergely L, Sulák A, Borbényi Z, Lévai D, Schneider T, Pettendi P, Bodai E, Szerafin L, Rejtő L, Bátai Á, Dömötör MÁ, Sánta H, Plander M, Szendrei T, Hamed A, Lázár Z, Pauker Z, Radványi G, Kiss A, Körösmezey G, Jakucs J, Dombi PJ, Simon Z, Klucsik Z, Gurzó M, Tiboly M, Vidra T, Ilonczai P, Bors A, Andrikovics H, Egyed M, Székely T, Masszi A, Alpár D, Matolcsy A, Bödör C. László T, et al. Among authors: balogh a. J Pathol Clin Res. 2024 Jan;10(1):e351. doi: 10.1002/cjp2.351. Epub 2023 Nov 21. J Pathol Clin Res. 2024. PMID: 37987115 Free PMC article.
Screening and monitoring of the BTKC481S mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy.
Bödör C, Kotmayer L, László T, Takács F, Barna G, Kiss R, Sebestyén E, Nagy T, Hegyi LL, Mikala G, Fekete S, Farkas P, Balogh A, Masszi T, Demeter J, Weisinger J, Alizadeh H, Kajtár B, Kohl Z, Szász R, Gergely L, Gurbity Pálfi T, Sulák A, Kollár B, Egyed M, Plander M, Rejtő L, Szerafin L, Ilonczai P, Tamáska P, Pettendi P, Lévai D, Schneider T, Sebestyén A, Csermely P, Matolcsy A, Mátrai Z, Alpár D. Bödör C, et al. Among authors: balogh a. Br J Haematol. 2021 Jul;194(2):355-364. doi: 10.1111/bjh.17502. Epub 2021 May 21. Br J Haematol. 2021. PMID: 34019713
Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax.
Kotmayer L, László T, Mikala G, Kiss R, Lévay L, Hegyi LL, Gróf S, Nagy T, Barna G, Farkas P, Weisinger J, Nagy Z, Balogh A, Masszi T, Demeter J, Sulák A, Kohl Z, Alizadeh H, Egyed M, Pettendi P, Gergely L, Plander M, Pauker Z, Masszi A, Matolcsy A, Szász R, Bödör C, Alpár D. Kotmayer L, et al. Among authors: balogh a. Int J Mol Sci. 2023 Mar 18;24(6):5802. doi: 10.3390/ijms24065802. Int J Mol Sci. 2023. PMID: 36982875 Free PMC article.
Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel.
Szabo D, Balogh A, Gopcsa L, Giba-Kiss L, Lakatos G, Paksi M, Reti M, Takacs P, Heteren PV, Zadoyan G, Holtkamp S, Overstijns T, Miltenyi S, Remenyi P, Nagy G. Szabo D, et al. Among authors: balogh a. RMD Open. 2024 Oct 23;10(4):e004727. doi: 10.1136/rmdopen-2024-004727. RMD Open. 2024. PMID: 39448205 Free PMC article.
Impact of Myc-Altered Pathology on Radiation Therapy Efficacy Among Patients With Relapsed/Refractory Large-B Cell Lymphoma: A Collaborative Study by ILROG.
Tseng YD, Stevenson P, Nguyen B, Li DC, Lee DY, Paydar I, Nakashima J, Balogh A, Ravella R, Barbour AB, Post C, Ababneh H, Pinnix CC, Ballas LK, Binkley MS, Dedeckova K, Hoppe RT, Patel C, Nabavizadeh N, Kelsey CR, Kumar KA, Landsburg D, Figura NB, Lo AC, Plastaras JP. Tseng YD, et al. Among authors: balogh a. Int J Radiat Oncol Biol Phys. 2024 Nov 15:S0360-3016(24)03642-3. doi: 10.1016/j.ijrobp.2024.11.072. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 39549763
Transition is associated with lower disease activity, fewer relapses, better medication adherence, and lower lost-to-follow-up rate as opposed to self-transfer in pediatric-onset inflammatory bowel disease patients: results of a longitudinal, follow-up, controlled study.
Tóbi L, Prehoda B, Balogh AM, Nagypál P, Kovács K, Miheller P, Iliás Á, Dezsőfi-Gottl A, Cseh Á. Tóbi L, et al. Among authors: balogh am. Therap Adv Gastroenterol. 2024 May 31;17:17562848241252947. doi: 10.1177/17562848241252947. eCollection 2024. Therap Adv Gastroenterol. 2024. PMID: 39156978 Free PMC article.
591 results